PR Newswire
LAS VEGAS, Jan. 26, 2026
The RET fusion-targeted therapy market is set for strong expansion, driven by growing awareness of the oncogenic role of RET gene fusions and encouraging clinical trial outcomes. With the approval of targeted agents such as selpercatinib and pralsetinib for RET fusion-positive tumors, oncology care is increasingly moving toward precision-driven approaches. Additionally, the launch of emerging therapies such as Sacituzumab tirumotecan (Merck & Co.), EP0031 (Ellipses Pharma), and others will further propel the market growth.
LAS VEGAS, Jan. 26, 2026 /PRNewswire/ — DelveInsight’s RET Fusion Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as NSCLC, medullary thyroid cancer, and other cancers driven by RET fusions. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging RET fusion targeted therapies, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
Key Takeaways from the RET Fusion Targeted Therapies Market Report
- The total market size of RET fusion targeted therapies in the leading markets is expected to surge significantly by 2034.
- In 2024, the United States holds the largest share of the RET fusion targeted therapies market among the 7MM.
- The report provides the total potential number of patients in the indications, such as NSCLC, medullary thyroid cancer, and other cancers driven by RET fusions.
- As per DelveInsight’s analysis, over 200K adults in the US are estimated to be affected with lung cancer in 2024. Lung cancer remains the leading cause of cancer-related deaths, with NSCLC accounting for nearly 80-85% of all cases. Additionally, RET fusions are present in approximately 1-2% of NSCLC patients.
- Leading RET fusion targeted therapies companies, such as Merck & Co., Ellipses Pharma, and others, are developing novel RET fusion targeted therapies that can be available in the RET fusion targeted therapies market in the coming years.
- Some of the key RET fusion targeted therapies in clinical trials include Sacituzumab tirumotecan, EP0031, and others.
Discover how large is the eligible patient pool for RET fusion targeted therapies @ https://www.delveinsight.com/report-store/ret-fusion-market-forecast?utm_source=cision&utm_medium=pressrelease&utm_campaign=spr
Key Factors Driving the RET Fusion Targeted Therapies Market
- Rising Prevalence and Identification of RET-Driven Cancers: The increasing incidence of cancers with RET fusions, particularly NSCLC and certain thyroid cancers, expands the eligible patient population for RET-targeted therapies. Improved genomic profiling in oncology is uncovering more patients harboring RET gene fusions, which were previously undiagnosed or misclassified.
- Expansion of Precision Oncology and Biomarker-Driven Treatment Paradigms: Precision medicine approaches are fundamental drivers, as therapies such as selpercatinib (RETEVMO) and pralsetinib (GAVRETO) target the specific oncogenic driver (RET fusion) rather than the tumor’s tissue of origin, thereby shifting cancer care toward personalized treatment.
- Launch of Emerging Therapies: The dynamics of the RET fusion-targeted therapies market are expected to change in the coming years with the launch of drugs such as Sacituzumab tirumotecan (Merck & Co.), EP0031 (Ellipses Pharma), and others.
RET Fusion Targeted Therapies Market Analysis
- The treatment landscape for RET fusion-positive cancers has advanced significantly with the approval of targeted RET inhibitors, including selpercatinib and pralsetinib.
- These therapies represent a major step forward in precision oncology, offering more effective and personalized options compared with conventional chemotherapy.
- RET inhibitors have demonstrated strong clinical efficacy in RET fusion-positive NSCLC and thyroid cancer, with ongoing trials exploring their potential across additional tumor types.
- Their integration into routine clinical practice reflects a broader shift toward molecularly guided treatment strategies, improving patient outcomes while reducing the toxicity associated with traditional therapies.
- As personalized medicine continues to gain traction, treatments targeting specific genetic alterations, such as RET fusions, are expected to play a central role in transforming cancer care.
- Continued research and deeper understanding of genetic drivers are likely to further expand the market, contributing to improved survival rates and enhanced quality of life for patients with RET-driven cancers.
Learn more about which drug has the largest market share in RET fusion therapies @ RET Fusion Targeted Therapies Analysis
RET Fusion Targeted Therapies Competitive Landscape
Some of the RET fusion targeted therapies in clinical trials include Sacituzumab tirumotecan (Merck & Co.), EP0031 (Ellipses Pharma), and others.
Merck & Co.’s Sacituzumab tirumotecan (MK-2870) is an investigational antibody-drug conjugate designed to target trophoblast cell-surface antigen 2 (TROP2), coupling a monoclonal antibody with a belotecan-based cytotoxic payload. The program is being co-developed with Sichuan Kelun-Biotech and has advanced to Phase III clinical evaluation in non-small cell lung cancer (NSCLC).
The ongoing Phase III trial is assessing sacituzumab tirumotecan versus standard chemotherapy options, including docetaxel or pemetrexed, in previously treated NSCLC patients harboring EGFR exon 19 deletions or exon 21 L858R mutations, as well as other oncogenic drivers such as ALK, ROS1, BRAF V600E, NTRK, MET exon 14 skipping mutations, RET rearrangements, and uncommon EGFR variants. The study is designed to determine therapeutic benefit across these molecularly defined subpopulations.
Ellipses Pharma’s EP0031 is a next-generation, highly selective RET inhibitor currently being investigated in a Phase I/II clinical trial in adults with advanced solid tumors characterized by RET alterations, including NSCLC. At ASCO 2024, Phase I findings presented in May 2024 indicated a favorable safety and tolerability profile for EP0031. No dose-limiting toxicities or treatment-related fatalities were reported. Most treatment-emergent adverse events were mild to moderate (Grade 1-2), with only a limited number of Grade 3 events. Adverse events were generally manageable with temporary treatment interruptions, with no treatment discontinuations due to toxicity and only a small proportion of patients requiring dose reductions. These data support the continued clinical advancement of EP0031 in RET-driven cancers.
The anticipated launch of these emerging therapies are poised to transform the RET fusion targeted therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the RET fusion targeted therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about which companies are developing next-generation RET inhibitors, visit @ RET Fusion Targeted Therapies Treatment
What are RET Fusion Targeted Therapies?
RET fusion-targeted therapies are precision cancer treatments designed to inhibit signaling driven by rearranged during transfection (RET) gene fusions, which act as oncogenic drivers in multiple solid tumors. These fusions result from chromosomal rearrangements that constitutively activate the RET tyrosine kinase, promoting uncontrolled cell growth and survival. RET fusion-positive cancers are most commonly seen in non-small cell lung cancer (NSCLC) and thyroid cancers, but are also identified across a range of other solid tumors. Targeted therapies, particularly highly selective RET inhibitors, work by specifically blocking RET kinase activity, thereby suppressing tumor proliferation while minimizing off-target toxicity seen with older multikinase inhibitors. The advent of these therapies has significantly improved clinical outcomes, offering higher response rates, durable disease control, and better tolerability for patients with RET fusion-driven malignancies.
RET Fusion Targeted Therapies Epidemiology Segmentation
The RET fusion targeted therapies market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020-2034 across the leading markets. The RET fusion targeted therapies target patient pool is segmented into:
- Total Cases in Selected Indications for RET Fusion Targeted Therapies
- Total Eligible Patient Pool in Selected Indications for RET Fusion Targeted Therapies
- Total Treated Cases in Selected Indications for RET Fusion Targeted Therapies
RET Fusion Targeted Therapies Report Metrics
Details
Study Period
2020-2034
RET Fusion Targeted Therapies Report Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Indications Covered in the Report
NSCLC, medullary thyroid cancer, and other cancers driven by RET fusions
RET Fusion Targeted Therapies Target Patient Pool Segmentation Total Cases in Selected Indications for RET Fusion Targeted Therapies, Total Eligible Patient Pool in
Selected Indications for RET Fusion Targeted Therapies, and Total Treated Cases in Selected
Indications for RET Fusion Targeted Therapies
Key RET Fusion Targeted Therapies Companies
Merck & Co., Ellipses Pharma, Eli Lilly, Rigel Pharmaceuticals, and others
Key RET Fusion Targeted Therapies
Sacituzumab tirumotecan, EP0031, RETEVMO, GAVRETO, and others
Scope of the
RET Fusion Targeted Therapies
Market Report
- RET Fusion Targeted Therapies Therapeutic Assessment: RET Fusion Targeted Therapies’ current marketed and emerging therapies
- RET Fusion Targeted Therapies Market Dynamics: Conjoint Analysis of Emerging RET Fusion Targeted Therapies Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, RET Fusion Targeted Therapies Market Access and Reimbursement
Discover what’s the status of Phase I/II/III RET fusion therapy clinical trials @ RET Fusion Targeted Therapies Clinical Trials
Table of Contents
1
RET Fusion Targeted Therapies Market Key Insights
2
RET Fusion Targeted Therapies Market Report Introduction
3
Executive Summary
4
Key Events
5
Market Forecast Methodology
6 RET Fusion Targeted Therapies Market Overview at a Glance in the 7MM
6.1
Market Share (%) Distribution by Indication in 2020
6.2
Market Share (%) Distribution by Indication in 2034
7 RET Fusion Targeted Therapies: Background and Overview
7.1
Introduction
7.2
Evolution of RET Fusion Targeted Therapies
7.3
Treatment
8
Target RET Fusion Targeted Therapies Patient Pool
8.1
Key Findings
8.2
Assumptions and Rationale: 7MM
8.3
Epidemiology Scenario in the 7MM
8.3.1 Total Cases in Selected Indications for RET Fusion Targeted Therapies in the
7MM
8.3.2 Total Eligible Patient Pool in Selected Indications for RET Fusion Targeted
Therapies in the 7MM
8.3.3 Total Treated Cases in Selected Indications for RET Fusion Targeted Therapies
in the 7MM
8.4
United States
8.4.1 Total Cases in Selected Indications for RET Fusion Targeted Therapies in the
US
8.4.2 Total Eligible Patient Pool in Selected Indications for RET Fusion Targeted
Therapies in the US
8.4.3 Total Treated Cases in Selected Indications for RET Fusion Targeted Therapies
in the US
8.5
EU4 and the UK
8.6
Japan
9
Marketed RET Fusion Targeted Therapies
9.1
Key Competitors
9.2
GAVRETO (pralsetinib): Rigel Pharmaceuticals
9.2.1
Product Description
9.2.2
Regulatory Milestones
9.2.3
Other Developmental Activities
9.2.4
Clinical Development
9.2.5
Safety and Efficacy
9.3
RETEVMO (Selpercatinib): Eli Lilly
List of drugs to be continued in the final report…
10
Emerging RET Fusion Targeted Therapies
10.1
Key Competitors
10.2
Sacituzumab tirumotecan: Merck & Co.
10.2.1
Drug Description
10.2.2
Other Developmental Activity
10.2.3
Clinical Trial Information
10.2.4
Safety and Efficacy
10.2.5
Analyst’s View
10.3
EP0031: Ellipses Pharma
List of drugs to be continued in the final report…
11 RET Fusion Targeted Therapies Market: the 7MM Analysis
11.1
Key Findings
11.2
RET Fusion Targeted Therapies Market Outlook
11.3
Attribute Analysis
11.4
Key RET Fusion Targeted Therapies Market Forecast Assumptions
11.5
Total Market Size of RET Fusion Targeted Therapies in the 7MM
11.6
The United States RET Fusion Targeted Therapies Market Size
11.6.1 Total Market Size of RET Fusion Targeted Therapies in the United States
11.6.2 Market Size of RET Fusion Targeted Therapies by Therapies in the United
States
11.7
EU4 and the UK RET Fusion Targeted Therapies Market Size
11.8
Japan RET Fusion Targeted Therapies Market Size
12
RET Fusion Targeted Therapies Market Unmet Needs
13
RET Fusion Targeted Therapies Market SWOT Analysis
14
KOL Views on RET Fusion Targeted Therapies
15
RET Fusion Targeted Therapies Market Access and Reimbursement
15.1
United States
15.2
EU4 and the UK
15.3
Japan
16
Acronyms and Abbreviations
17
Bibliography
18
RET Fusion Targeted Therapies Market Report Methodology
Related Reports
Non-small Cell Lung Cancer Market
The NSCLC market size has undergone a revolutionary transformation over the last decade, driven by an increase in incident cases, the continuous adoption of approved therapies primarily immune checkpoint inhibitors, the anticipated introduction of premium-priced treatments, and growing awareness of mutations such as KRAS, BRAF, c-Met, and others. NSCLC is increasingly becoming a biomarker-driven market. EGFR is one of the profitable biomarker segments, with blockbuster therapies such as TAGRISSO. TAGRISSO is now the dominant EGFR inhibitor, selling nearly USD 6 billion annually. The non-small cell lung cancer market size is estimated to be ~USD 30 billion in the leading markets (the US, EU4, the UK, and Japan) in 2024. It is anticipated to grow with a significant CAGR during the study period (2020-2034). Leading NSCLC companies include Daiichi Sankyo, AstraZeneca, Gilead Sciences, BieGene, AbbVie, Roche, Merck, Novartis, Pfizer, Takeda Pharmaceuticals, Eli Lilly, BerGenBio, GlaxoSmithKline, and Duality biologics, among others.
Non-small Cell Lung Cancer Clinical Trial Analysis
Non-small Cell Lung Cancer Pipeline Insight – 2025 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key non-small cell lung cancer companies, including BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, BridgeBio Pharma, Abbvie, Pfizer, Eli Lilly and Company BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Bristol Myers Squibb, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene, Ono Pharmaceutical, Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, among others.
Medullary Thyroid Cancer Market
Medullary Thyroid Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key medullary thyroid cancer companies, including Bayer HealthCare, TYK Medicines, Inc., Applied Pharmaceutical Science, CSPC ZhongQi Pharmaceutical Technology Co., Ltd, among others.
Antibody Drug Conjugates Market
Antibody Drug Conjugates Market Size, Target Population, Competitive Landscape & Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key ADC companies, including AbbVie, Genmab, Daiichi Sankyo, AstraZeneca, Astellas, Roche, Pfizer (Seagen), Takeda, Ambrx, Daiichi Sankyo, Merck, Eisai, Bristol-Myers Squibb, Sanofi, NBE-Therapeutics, ImmunoGen, Inc., Seagen Inc., ADC Therapeutics, Mythic Therapeutics, Sutro Biopharma, Sorrento Therapeutics, Inc., Peak Bio, Regeneron Pharmaceuticals, Asana BioSciences, Tanabe Research Laboratories USA, OBI Pharma, Navrogen, Inc., among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakur [email protected] +14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/ret-fusion-targeted-therapies-market-set-for-robust-growth-by-2034-amid-precision-oncology-shift–delveinsight-302667632.html
Tengo varias preguntas sobre esto a ver si me podiais aclarar:
-¿Puedo hacer un ingreso regular de 800 euros y me cobran 0euos de comisiones y mto.?
-¿Puedo sacar el dinero cuando quiera?,¿todo ó tengo entendido que hay que mantener un mínimo de 100 euros los 30 meses?
-No necesito pero me obligan a sacar una tarjeta de débito que me cuesta 11 euros el primer año y 22 euros la renovación, también otra de credito que me cuesta 0 euros el primer año y 35 euros la renovación.
¿Hay que mantenerlas 13 meses?
¿Puedo cancelar alguna de ellas desde el principio?
¿Puedo cancelar alguna de ellas antes de la renovación?
¿Hay alguna tarjeta de credito más barata?
Aparte de la cuenta nómina he visto que también que para que te den la tv también se puede sacar una cuenta tarifa plana básica o personal, ¿sabeis algo de estas cuentas?¿que requisitos tienen?
Muchas gracias a todos por responder
Yo fui a informarme y te cuento. Únicamente admiten los ingresos regulares en el caso de que seas autónomo. Te abren una cuenta Tarifa Plana Cero que está exenta de comisiones y presenta alguna ventaja más. Sobre dejar un mínimo de saldo en la cuenta no es necesario, pero sí te obligan a mantener varias tarjetas durante los 30 meses con un coste aproximado de 100 euros anuales.
hola buenas!
me llamo javi y estoy dudando de que banco, me puede dar mas beficios, sin sorpresas por domiciliar la nomina, ya que llevo años en la caixa y no me da nada ningun beneficio. es mas me rechazan los prestamos que solicito, ni siquiera una targeta de credito, por alegan de que siempre esta a cero la cuenta, yo cuando cobro la nomina dejo el dinero para los pagos, y saco el resto, pues no me fio, de que un dia me quede sin dinero, ya que esta todo muy mal, corre riesgo mi dinero o mis ahorros en el banco?? muchas gracias y un cordial saludo.
javi
NO TE EXTRAÑE QUE NO TE DEN LOS PTMOS, PORQUE LO QUE VEN ES QUE NO TIENES CAPACIDAD DE AHORRO PORQUE SIEMPRE DEJAS LA CTA. EN MINIMOS, ASI NINGUN BANCO TE LO VA A CONCEDER. TAMBIEN ES VERDAD QUE LA CAIXA, COMO TANTAS OTRAS CAJAS, TIENE EL PUÑO CERRADO PARA LOS RIESGOS, PARA REMONTAR. NO TE PREOCUPES, QUE POR UNA NOMINA NO CREO QUE NINGUN BANCO SE COJA LAS MANOS. LOS QUE SE TIENEN QUE PREOCUPAR SON LOS QUE TIENEN DÉPÓSITOS Y FONDOS EN BANCOS DE DUDOSA ACTIVIDAD. LA GENTE SE PIENSA QUE PORQUE LES DEN UN 7% YA ES UN GRAN BANCO Y SE EQUIVOCAN. LO QUE LES PASA ES QUE EL BANCO DE ESPAÑA LES PRESTA EL DINERO MAS CARO Y POR ESO OPTAN POR CONSEGUIRLO EN EL MERCADO MONETARIO, Y SI EL BANCO DE ESPAÑA NO SE FIA DE ELLOS, VA Y SE FIA LA GENTE. QUE LOS BANCOS NOES LA ADMON PUBLICA, ABRAN OS OJOS.
Hola , cuando vallais al banco queos dejen lo que hay que pagar de irpf y de iva sobre el valor de la tele ya que en la mayoria de bancos esto no lo dicen y luego llagan las sorpresas .A mi ya me ha pasado con la promoción del portatil y nunca me hablaros de esto . Cuidado
Yo he estado calculando y la tele entre unas cosas y otras te sale sobre unos 250euros que tampoco regalan tanto .Hay oficinas en las que han dado la occión de poner un dinero a plazo fijo a 12meses de 9300euros o 6800euros a 18 meses.
No es ningún chollo. Te obligan a contratar dos tarjetas de crédito que tienes que pagar porque las tienes que mantener 13 meses por lo menos y además llevan unos costes desproporcionados si las utilizas. En total, no usando las tarjetas y anulándolas una vez cumplidos los 13 meses puedes ahorrar unos 38 euros con respecto al precio de ese televisor en una gran superficie. Y además luego vendrá que te cobran para hacienda la retención correspondiente, por lo que probablemente incluso en las mejores condiciones te cueste más que si ahorras un poco y lña compras directamente.
Creó que teneis toda la razón, que aqui no te regalan nada, ya que a mí me paso con unas sartenes que regalaban el banco bilbao, que al final entre el irpf y el descuento de Hacienda, al final me salieron caras, así es que no os tomen el pelo, que al final siempre esta la letra pequeña que es la que nos joroba, por no decir otra cosa.
Yo saque el portatil y ahora me he sacado la TV LCD 32. Estas promos no hay que declararlas. No es obligado domiciliar nomina. Si, meter en la cuenta 800€ todos los meses en un margen de 10 dias. Cero matacero, pero cero,cero, cero de gastos de mantenimiento, ni por recibos, ni por el correo a casa, ni por transfer. Las tarjets gratis el 1er año. Resto fuera. Dadas de baja Menos la de debito. Banesto no pierde nada, ganar, gana clientes que es el proposito de esta promo. Precio de portatil y tv 32 en mercao unos 900€ los 2. En banest 197€. Los hay mejores, nos ha jodio! portatiles a 1200€, TV LCD 32 a 1000€. Señores, son lentejas. Relacion calida-precio-promo es cojonud…….Un saludit a los viandantes.
hola , no se si llegara mi comentario pero os voi a esplicar. esto es el cuento de la abuela. mira yo tengo el portatil. y he cogio tab la tele, pero sabeis ke?, me ha pasado de todo. os esplico. primero me cobran 74 euros y 25 euros de unas tarjetas que yo no las he visto aparecer por mi casa , me cabreo con el banco. llamo y pido esplicaciones. me dicen que van en la promocion, nunca jamas nadie me informo de las tarjetas, no me devuelven el dinero. me cabreo y me dicen que llame aun numero de tefono para darlas de baja, se pasan los dias, intentamos darlas de baja. largas y larga, que si este numero de tefono que si el otro bla bla bla. conseguimos hablar y nos dicen que tenemos que cambiar el contrato a tarifa plana o no se ke historias, llamando al banco se pasan los dias, largas y largas. me cabreo y estoi por suspender todo, me dicen que si lo quiero cambiar y dar de baja las tarjetas que nunca he tenido. tengo que pagar comisiones cada seis meses de doce y pico euros, y que si no quiero que me cobren comisiones tengo que ir todos los meses al banco a hacerlo yo, ufffffffffff.aun hay mas. me dan de baja y me hacen la tarifa plana, se equivocan un monton de veces. me hacen pasar muchos cabreos.y al final cuando llego a casa me han cobrado 25, 50 euros. y llamo por telefono y se lo digo , me dicen claro por dar de baja la otra cuenta , la madre que los pario. ladrones. o sea os digo que la tele no sale regalada, se la cobran y muy bien cobrada , nadie da nada por nada. en cuento termine de pagar lo que debo quito todas las cuentas del banesto.espero que alguien me lea y que me conteste gracias .
Banesto ha jodido a mi marido y a un amigo tambien. Para mi, despues de Banco de Andalucía son los peores. Y quieran creerlo o no ni la television ni el portátil te lo regalan.. como no cumplas cualquiera de las reglas te sancionan con 300 y pico de euros.. porque nos hemos mudado de casa y los recibos domiciados se cortaron «temporalmente» la sancion fue de mas de 300 euros.. y el cabreo q te llevas cuando ves lo q te han descontado y luego para ir a reclamarlos.. y como te tratan !! en fin.. espero que Banesto sea lo primero en undirse en el fin del mundo!!
CHOLLO!!!!!!!!!JAJAJAJAJA…….NO ES NINGUN CHOLLO!!!!!!! te cobran 100 € de gastos de manipulacion, mas 150 € en tarjetas durante 2 años, mas 6 € mensuales de mantenimiento de cuenta durante 30 meses, total que pagas 630 Euros por un ordenador o una TV que su valor seguro que no llega a 500 €. Y encima si vas a cancelar la cuenta cuando cumples los 30 meses requeridos te hacen esperar dos horas para decirte que no tienen linea de telefono para dar de baja la cuenta, cosa que no para nunca cuando vas a contratarlo. Y del trato que dispensan….., es el mismo que si vas con un fajo de billetes de 500 € por los CO-JONES
Banesto «premia», menuda falacia…
No hay ningún banco que premie a nadie.
BANESTO NECESITA NUESTRAS NÓMINAS, Y EN CUANTO VAS UN POCO JUSTO, COMO BUENOS JUDÍOS Y ÁVAROS QUE SON, TE ACOSAN Y MACHACAN, Y TE SACAN HASTA LAS ENTRAÑAS EN COMISIONES.
DESPUÉS EL ESTADO APOYA A LOS BANCOS, CON LA EXCUSA DE QUE SI CAEN LOS BANCOS CAEMOS TODOS. LOS BANCOS NECESITAN UN BOICOT DE VEZ EN CUANDO, PARA QUE NO NOS RESTREGUEN POR LA CARA SUS BENEFICIOS.
POR CIERTO, LO QUE MÁS FASTIDIA A UN BANCO ES UNA RECLAMACIÓN EN LA OFICINA DEL CONSUMIDOR Y OTRA AL BANCO DE ESPAÑA.
ES POR DAR PISTAS…